Investorideas.com

Investorideas.com
Breaking News

Investorideas.com newswire

Wednesday, December 17, 2014

Biotech Research News: H.C. Wainwright & Co. Initiates Coverage of GenSpera (OTCQB:GNSZ) with a Buy Rating

Biotech Research News: H.C. Wainwright & Co. Initiates Coverage of GenSpera (OTCQB:GNSZ) with a Buy Rating



New York, NY - December 17, 2014 (Investorideas.com Biotech Newswire) Market Exclusive announces that H.C. Wainwright & Co has initiated coverage with a Buy rating of GenSpera, Inc. (OTCQB:GNSZ) and a 12-month target price of $2.

According to the H.C Wainwrights & Co. report, "if successful, Genspera's platform could help provide a novel way to deliver drugs with higher efficiency to specific hard-to-treat cancers, such as HCC and GBM."

GenSpera, Inc., headquartered in San Antonio, Texas, is a biotechnology company specializing in the development of targeted prodrug agents for the treatment of various solid cancers.

About Market Exclusive
Market Exclusive is a financial portal geared to engaging discussion on current financial topics. Market Exclusive is not an investment advisor.

The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

SOURCE: Market Exclusive


About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types.

The US Food and Drug Administration (FDA) granted Orphan Drug designation in 2013 for the evaluation of mipsagargin in patients with hepatocellular carcinoma. Mipsagargin Phase II clinical trials are underway in both hepatocellular carcinoma (liver cancer) and glioblastoma patients (brain cancer).

For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.

Company presentations are available at: http://www.genspera.com/


Visit this company: www.genspera.com

More info on GNSZ at Investorideas.com Visit: http://www.investorideas.com/CO/GNSZ/


Disclaimer/ Disclosure: Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera (GNSZ) has engaged Investor Ideas for PR and news publication effective June 18, 2014 (compensation of five thousand per month and average of eleven thousand five hundred 144 shares per month)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Become an Investorideas.com Member and access our 14 online stock directories 24/7 –biotech, mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/

Any redistribution or publishing of information from our newsletter alerts and e-mails without the written consent of Investorideas.com is strictly forbidden 


Post a Comment